
Vyne Therapeutics (VYNE) Stock Forecast & Price Target
Vyne Therapeutics (VYNE) Analyst Ratings
Bulls say
VYNE Therapeutics Inc. is showing promising clinical advancements, particularly with its product candidate VYN202, which demonstrated a four-point improvement in joint pain and a significant 48% reduction in serum C-reactive protein among treated patients, indicating effective management of immuno-inflammatory conditions. The company's financial stability is emphasized by the maintenance of approximately $40 million in cash, which provides the necessary liquidity to support ongoing operations and strategic development initiatives. These factors, combined with the encouraging data from ongoing trials, contribute to a positive outlook for the company's stock performance.
Bears say
VYNE Therapeutics Inc. has encountered significant challenges, as evidenced by its recent Phase 2b trial results, which failed to meet the primary endpoint for vitiligo and revealed a concerningly high vehicle effect coupled with an elevated dropout rate among participants. The company's decision to discontinue treatment in the ongoing extension phase of the trial and terminate the Phase 2b trial indicates a substantial setback in its development pipeline. This series of events has prompted a downgrade of VYNE's stock rating, highlighting increased uncertainty surrounding the company's ability to advance its immuno-inflammatory therapies successfully.
This aggregate rating is based on analysts' research of Vyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Vyne Therapeutics (VYNE) Analyst Forecast & Price Prediction
Start investing in Vyne Therapeutics (VYNE)
Order type
Buy in
Order amount
Est. shares
0 shares